Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in generalized myasthenia gravis with inadequate response to immunosuppressants
2009-014669-13Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eculizumab in myasthenia gravis (MG) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Started Oct 2009; status: terminated.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2009-014669-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014669-13.